National Hepatology & Tropical Medicine Research Institute Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Cairo Egypt

Organization Overview

First Clinical Trial
2002
NCT00158496
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fellow at The National Hepatology and Tropical Research medicine institute | National Hepatology and Tropical Medicine Research Institute | National Hepatology & Tropical Medicine Research Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 3)

Cholecystitis (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Hepatorenal Syndrome (Phase 3)

Renal Insufficiency (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 23